CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials.

Babikir KheiriMohammed OsmanAhmed AbdallaTarek HaykalPranay V PandrangiAdam ChahineSahar AhmedKhansa OsmanGhassan BachuwaMustafa HassanDeepak L Bhatt

Published in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2018)

In patients undergoing stent implantation, MACE with genotype-guided therapy was not significantly reduced; however, there was a signal towards reduction of MACE in ACS patients, as well as a lower rate of MI, though this will require further confirmation in adequately powered trials.

Keyphrases

antiplatelet therapy
acute coronary syndrome
patients undergoing
end stage renal disease
percutaneous coronary intervention
ejection fraction
healthcare
newly diagnosed
chronic kidney disease
prognostic factors
quality improvement
bone marrow
pain management
chronic pain
replacement therapy